Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-12-001404
Filing Date
2012-05-10
Accepted
2012-05-10 15:45:22
Documents
11
Period of Report
2012-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zk1211437.htm 10-Q 1080838
2 EXHIBIT 31.1 exhibit311.htm EX-31.1 12750
3 EXHIBIT 31.2 exhibit312.htm EX-31.2 12825
4 EXHIBIT 32.1 exhibit321.htm EX-32.1 7727
5 EXHIBIT 32.2 exhibit322.htm EX-32.2 8064
  Complete submission text file 0001178913-12-001404.txt   3153633

Data Files

Seq Description Document Type Size
6 INSTANCE DOCUMENT bicl-20120331.xml EX-101.INS 359624
7 TAXONOMY EXTENSION SCHEMA bicl-20120331.xsd EX-101.SCH 19136
8 TAXONOMY EXTENSION CALCULATION LINKBASE bicl-20120331_cal.xml EX-101.CAL 45335
9 AXONOMY EXTENSION LABEL LINKBASE bicl-20120331_lab.xml EX-101.LAB 243398
10 TAXONOMY EXTENSION PRESENTATION LINKBASE bicl-20120331_pre.xml EX-101.PRE 91241
11 TAXONOMY EXTENSION DEFINITION LINKBASE bicl-20120331_def.xml EX-101.DEF 36063
Mailing Address BECK SCIENCE CENTER 8 HARTOM STREET, HAR HOTZVIM JERUSALEM L3 97775
Business Address BECK SCIENCE CENTER 8 HARTOM STREET, HAR HOTZVIM JERUSALEM L3 97775 972-2-548-6555
BIOCANCELL THERAPEUTICS INC. (Filer) CIK: 0001451980 (see all company filings)

EIN.: 204630076 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-53708 | Film No.: 12830073
SIC: 2834 Pharmaceutical Preparations